{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:35:50Z","timestamp":1794432950830,"version":"4.9.1"},"reference-count":74,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect pathogenesis, prognosis, and therapeutic response. In this systematic review, we searched 3 databases and selected 32 articles that described mutations in MCL patients. We then conducted a meta-analysis using a Bayesian multiregression model to analyze patient-level data in 2127 MCL patients, including prevalence of mutations. In tumor or bone marrow samples taken at diagnosis or baseline, ATM was the most frequently mutated gene (43.5%) followed by TP53 (26.8%), CDKN2A (23.9%), and CCND1 (20.2%). Aberrations were also detected in IGH (38.4%) and MYC (20.8%), primarily through cytogenetic methods. Other common baseline mutations were NSD2 (15.0%), KMT2A (8.9%), S1PR1 (8.6%), and CARD11 (8.5%). Our data also show a change in mutational status from baseline samples to samples at disease progression and present mutations of interest in MCL that should be considered for future analysis. The genes with the highest mutational frequency difference (&amp;gt;5%) are TP53, ATM, KMT2A, MAP3K14, BTK, TRAF2, CHD2, TLR2, ARID2, RIMS2, NOTCH2, TET2, SPEN, NSD2, CARD11, CCND1, SP140, CDKN2A, and S1PR1. These findings provide a summary of the mutational landscape of MCL. The genes with the highest change in mutation frequency should be included in targeted next-generation sequencing panels for future studies. These findings also highlight the need for analysis of serial samples in MCL. Patient-level data of prevalent mutations in MCL provide additional evidence emphasizing molecular variability in advancing precision medicine initiatives in MCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001350","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:40:07Z","timestamp":1593430807000},"page":"2927-2938","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3642-1897","authenticated-orcid":false,"given":"Holly A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Biostatistics, MD Anderson Cancer Center, University of Texas, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-8341","authenticated-orcid":false,"given":"Yucai","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhao","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael L.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"6","key":"2020062911394727300_B1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"2020062911394727300_B2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2020062911394727300_B3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"45","key":"2020062911394727300_B4","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2020062911394727300_B5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1080\/10428194.2016.1248965","article-title":"The molecular pathogenesis of mantle cell lymphoma","volume":"58","author":"Vogt","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020062911394727300_B6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PAP.0000000000000241","article-title":"Utility of cyclin D1 in the diagnostic workup of hematopoietic neoplasms: what can cyclin D1 do for us?","volume":"26","author":"Wang","year":"2019","journal-title":"Adv Anat Pathol"},{"issue":"491","key":"2020062911394727300_B7","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"key":"2020062911394727300_B8","first-page":"5","article-title":"TP53 mutations, but not deletion of TP53 and CDKN2A, have independent prognostic value in mantle cell lymphoma treated by the nordic (MCL2 and MCL3) regimen","volume":"102","author":"Eskelund","year":"2017","journal-title":"Haematologica"},{"issue":"17","key":"2020062911394727300_B9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020062911394727300_B10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"2020062911394727300_B11","author":"Zhang","year":"2017"},{"key":"2020062911394727300_B12","first-page":"S9","article-title":"Signaling pathways as therapeutic target in lymphomas","volume":"99","author":"Spina","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2020062911394727300_B13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","article-title":"Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types","volume":"7","author":"Shu","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"2020062911394727300_B14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1634\/theoncologist.2017-0020","article-title":"Clinical application of targeted deep sequencing in solid-cancer patients and utility for biomarker-selected clinical trials","volume":"22","author":"Kim","year":"2017","journal-title":"Oncologist"},{"key":"2020062911394727300_B15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2587","article-title":"Liquid biopsy in non-Hodgkin\u2019s lymphoma","volume":"37","author":"Melani","year":"2019","journal-title":"Hematol Oncol"},{"key":"2020062911394727300_B16","author":"Roschewski","year":"2018"},{"issue":"4","key":"2020062911394727300_B17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"2020062911394727300_B18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3389\/fonc.2019.00568","article-title":"Dynamic changes in gene mutational landscape with preservation of core mutations in mantle cell lymphoma cells","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"issue":"10","key":"2020062911394727300_B19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"36","key":"2020062911394727300_B20","doi-asserted-by":"crossref","first-page":"58638","DOI":"10.18632\/oncotarget.10716","article-title":"Gene mutations and actionable genetic lesions in mantle cell lymphoma","volume":"7","author":"Ahmed","year":"2016","journal-title":"Oncotarget"},{"issue":"30","key":"2020062911394727300_B21","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"2020062911394727300_B22","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"2020062911394727300_B23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1214\/08-AOAS191","article-title":"A weakly informative default prior distribution for logistic and other regression models","volume":"2","author":"Gelman","year":"2008","journal-title":"Ann Appl Stat"},{"issue":"7","key":"2020062911394727300_B24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"13","key":"2020062911394727300_B25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2020062911394727300_B26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.anndiagpath.2014.03.006","article-title":"Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and\/or 13q14","volume":"18","author":"Chapman-Fredricks","year":"2014","journal-title":"Ann Diagn Pathol"},{"issue":"9","key":"2020062911394727300_B27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma [published correction appears in Cancer Discov. 2019;9(11):1629]","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"4","key":"2020062911394727300_B28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020062911394727300_B29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020062911394727300_B30","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2020062911394727300_B31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic variations in mantle cell lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"2020062911394727300_B32","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2020062911394727300_B33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAI.0b013e3181bb9edf","article-title":"BCL6, MUM1, and CD10 expression in mantle cell lymphoma","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"12","key":"2020062911394727300_B34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2020062911394727300_B35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2010-01-263806","article-title":"Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling","volume":"116","author":"Hartmann","year":"2010","journal-title":"Blood"},{"key":"2020062911394727300_B36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/modpathol.2017.135","article-title":"CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course","volume":"31","author":"Hu","year":"2018","journal-title":"Mod Pathol"},{"issue":"7647","key":"2020062911394727300_B37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"9","key":"2020062911394727300_B38","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020062911394727300_B39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2020062911394727300_B40","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","article-title":"ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients","volume":"60","author":"Mareckova","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020062911394727300_B41","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2020062911394727300_B42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma","volume":"133","author":"Mart\u00edn-Garcia","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2020062911394727300_B43","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2020062911394727300_B44","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.clml.2018.11.007","article-title":"Aggressive leukemic non-nodal mantle cell lymphoma with P53 gene rearrangement\/mutation is highly responsive to rituximab\/ibrutinib combination therapy","volume":"19","author":"Mori","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"2020062911394727300_B45","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"11","key":"2020062911394727300_B46","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020062911394727300_B47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anndiagpath.2019.05.004","article-title":"TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant","volume":"41","author":"Sakhdari","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"25","key":"2020062911394727300_B48","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"5-6","key":"2020062911394727300_B49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"issue":"19","key":"2020062911394727300_B50","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020062911394727300_B51","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.3892\/or.2017.5891","article-title":"Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas","volume":"38","author":"Zlamalikova","year":"2017","journal-title":"Oncol Rep"},{"issue":"6","key":"2020062911394727300_B52","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"2020062911394727300_B53","unstructured":"HGNC: HUGO Gene Nomenclature Committee. https:\/\/www.genenames.org\/. Accessed 9 June 2019."},{"key":"2020062911394727300_B54","unstructured":"GeneCards Database . https:\/\/www.genecards.org\/. Accessed 9 June 2019."},{"key":"2020062911394727300_B55","unstructured":"NCBI BioProject . https:\/\/www.ncbi.nlm.nih.gov\/bioproject. Accessed 9 June 2019."},{"issue":"1","key":"2020062911394727300_B56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13073-016-0332-x","article-title":"Genetic pleiotropy in complex traits and diseases: implications for genomic medicine","volume":"8","author":"Gratten","year":"2016","journal-title":"Genome Med"},{"key":"2020062911394727300_B57","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2020062911394727300_B58","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2020062911394727300_B59","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"2020062911394727300_B60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1625.1625","article-title":"Rituximab and high-dose cytarabine do not counteract the adverse prognostic value of CDKN2A and TP53 deletions in autografted mantle-cell lymphoma patients. A European-MCL network study","volume":"124","author":"Delfau-Larue","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2020062911394727300_B61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic hypermutation and V(H) gene usage in mantle cell lymphoma","volume":"68","author":"Thors\u00e9lius","year":"2002","journal-title":"Eur J Haematol"},{"key":"2020062911394727300_B62","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-1-4939-9151-8_9","article-title":"MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR","volume":"1956","author":"Pott","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"45","key":"2020062911394727300_B63","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"2020062911394727300_B64","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2020062911394727300_B65","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.150.150","article-title":"A phase I trial of ibrutinib plus palbociclib in patients with previously treated mantle cell lymphoma","volume":"128","author":"Martin","year":"2016","journal-title":"Blood."},{"issue":"12","key":"2020062911394727300_B66","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1080\/10428194.2019.1612062","article-title":"A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma","volume":"60","author":"Martin","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020062911394727300_B67","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"8","key":"2020062911394727300_B68","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/gcc.22849","article-title":"Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: a multi-institutional study","volume":"59","author":"Streich","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"2020062911394727300_B69","article-title":"E3 ligase, UBR5, HECT domain mutations in lymphoma control maturation of B cells [published online ahead of print 23 April 2020]","author":"Swenson","journal-title":"Blood"},{"issue":"6","key":"2020062911394727300_B70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/ajh.25796","article-title":"Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients","volume":"95","author":"Zhao","year":"2020","journal-title":"Am J Hematol"},{"key":"2020062911394727300_B71","article-title":"Coding and non-coding drivers of mantle cell lymphoma identified through exome and genome sequencing [published online ahead of print 5 March 2020]","author":"Pararajalingam","journal-title":"Blood"},{"key":"2020062911394727300_B72","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"2","key":"2020062911394727300_B73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1081\/SAC-100002370","article-title":"How good is a normal approximation for rates and proportions of low incidence events?","volume":"30","author":"Carri\u00e8re","year":"2001","journal-title":"Commun Stat Simul Comput"},{"issue":"4","key":"2020062911394727300_B74","first-page":"419","article-title":"Calculating the probability of rare events: why settle for an approximation?","volume":"28","author":"Luft","year":"1993","journal-title":"Health Serv Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/2927\/1746572\/advancesadv2019001350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/2927\/1746572\/advancesadv2019001350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T23:13:37Z","timestamp":1696288417000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/2927\/461173\/Genetic-mutations-and-features-of-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":74,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001350","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]}}}